These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20683978)

  • 1. The curative efficiency of tenofovir for patients with chronic hepatitis B after failure of nucleoside/nucleotide analogues.
    Chen EQ; Tang H
    Hepatology; 2010 Aug; 52(2):802. PubMed ID: 20683978
    [No Abstract]   [Full Text] [Related]  

  • 2. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice.
    Lampertico P
    J Hepatol; 2009 Apr; 50(4):644-7. PubMed ID: 19231017
    [No Abstract]   [Full Text] [Related]  

  • 3. [Influence of nucleoside analogues resistance on anti-HBV treatment].
    Hou JL; Sun J
    Zhonghua Yi Xue Za Zhi; 2005 May; 85(17):1156-7. PubMed ID: 16029585
    [No Abstract]   [Full Text] [Related]  

  • 4. Does the presence of adefovir-resistant variants lead to failure of tenofovir monotherapy?
    Deterding K; Manns MP; Wedemeyer H
    J Hepatol; 2008 Nov; 49(5):862-3. PubMed ID: 18804309
    [No Abstract]   [Full Text] [Related]  

  • 5. [Efficacy of adefovir treatment in the lamivudine-resistant chronic hepatitis B patients].
    Chen CY; Tu XL; Cheng QH; Dai Y
    Zhonghua Gan Zang Bing Za Zhi; 2010 Dec; 18(12):942-3. PubMed ID: 21205485
    [No Abstract]   [Full Text] [Related]  

  • 6. Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B.
    Leemans WF; Ter Borg MJ; de Man RA
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():171-82. PubMed ID: 18081660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B genotypes and response to adefovir treatment in patients with HBV chronic infection.
    Scotto G; Fazio V
    J Infect; 2010 May; 60(5):399-401. PubMed ID: 20226208
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic hepatitis B--new goals, new treatment.
    Lai CL; Yuen MF
    N Engl J Med; 2008 Dec; 359(23):2488-91. PubMed ID: 19052131
    [No Abstract]   [Full Text] [Related]  

  • 9. What is the optimum dose of adefovir in the treatment of chronic hepatitis B infection?
    Simsek H; Shorbagi A; Balaban Y; Tatar G
    J Hepatol; 2008 Sep; 49(3):464-5. PubMed ID: 18644652
    [No Abstract]   [Full Text] [Related]  

  • 10. Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B.
    Marcellin P; Asselah T
    J Hepatol; 2005 Dec; 43(6):920-3. PubMed ID: 16246449
    [No Abstract]   [Full Text] [Related]  

  • 11. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
    Leemans WF; Janssen HL; Niesters HG; de Man RA
    J Viral Hepat; 2008 Feb; 15(2):108-14. PubMed ID: 18184193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
    Mohamadnejad M
    Arch Iran Med; 2006 Jan; 9(1):90-2. PubMed ID: 16649389
    [No Abstract]   [Full Text] [Related]  

  • 13. [Lamivudine, adefovir dipivoxil].
    Miyajima I; Sata M
    Nihon Rinsho; 2011 May; 69 Suppl 4():492-7. PubMed ID: 22096967
    [No Abstract]   [Full Text] [Related]  

  • 14. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
    Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
    Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Safety and efficacy of Entecavir combined with Adefovir in patients with chronic hepatitis B who fail to respond to nucleoside analog treatment].
    Yan L; Wang ZH; Yang J; Zhou B; Guo YB; Peng J; Sun J; Hou JL
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(6):1009-13. PubMed ID: 21690057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure.
    Garg H; Sarin SK; Kumar M; Garg V; Sharma BC; Kumar A
    Hepatology; 2011 Mar; 53(3):774-80. PubMed ID: 21294143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress and perspectives in treatment of chronic hepatitis B].
    Minami M; Okanoue T
    Nihon Rinsho; 2011 Apr; 69(4):737-41. PubMed ID: 21591432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The use of nucleotide analogues in treating patients with chronic hepatitis B].
    Wei L; Feng B
    Zhonghua Gan Zang Bing Za Zhi; 2006 May; 14(5):380-1. PubMed ID: 16732918
    [No Abstract]   [Full Text] [Related]  

  • 20. [New drugs of treatment of patients with chronic hepatitis B].
    Suzuki F
    Nihon Rinsho; 2011 May; 69 Suppl 4():512-4. PubMed ID: 22096971
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.